目的：分析复方血塞通联合康柏西普对病理性近视脉络膜新生血管(choroidal neovascularization，CNV)患者黄斑中心视网膜厚度(central macular retinal thickness，CMT)、荧光素眼底血管造影及最佳矫正视力(BCVA)的影响。

方法：根据不同治疗方法将60例60眼病理性CNV患者分为观察组(复方血塞通联合康柏西普治疗)与对照组(单纯康柏西普治疗)，各30例，比较两组患者治疗前后CMT、眼压(IOP)、CNV面积、BCVA及血清中血管内皮生长因子(VEGF)变化情况，统计随访期间并发症情况。

结果：观察组术后12wk视力恢复总有效率(97%)显著高于对照组的80%，差异有统计学意义(P<0.05)； 与术前比较，两组患者术后12wk时CMT、IOP、CNV面积及血清VEGF水平均显著下降，BCVA显著提高，差异有统计学意义(P<0.01)，且观察组术后上述指标均明显优于对照组，差异有统计学意义(P<0.01)。两组患者均无局部并发症及全身严重并发症发生。

结论：复方血塞通联合康柏西普能有效降低CMT及IOP，缩小CNV面积，显著提高视力。

AIM: To analyze the effect of compound xuesaitong combined with conbercept on central macular retinal thickness(CMT), fluorescein fundus angiography and best corrected visual acuity(BCVA)in pathological patients with choroidal neovascularization(CNV).

METHODS:A total of 60 cases(60 eyes)with pathological myopia and CNV who were admitted to our hospital during January to October 2016 were enrolled in the study. They were divided into observation group and control group, 30 cases in each group. Observation group was treated with compound xuesaitong combined with conbercept. Control group was treated with conbercept only. Changes of CMT, intraocular pressure(IOP), area of CNV, BCVA and serum vascular endothelial growth factor(VEGF)before surgery, 4 and 12wk after surgery were compared. Complications during follow-up were statistically analyzed.

RESULTS: At 12wk after surgery, the total effective rate was 97% in observation group, 80% in control group and the difference was significant(P<0.01). The CMT, IOP, area of CNV and serum VEGF levels were significantly lower or smaller than those before surgery while BCVA was significantly higher than that before surgery(P<0.01). There were no local complications of systematic severe complications.

CONCLUSION: Compound xuesaitong combined with conbercept can effectively reduce CMT and IOP, reduce the area of CNV and significantly improve visual acuity. Its anti-VEGF effect is obvious, safe and feasible.